CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental radiation drug targets tough blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 03:27 UTC
-
New hope for hard-to-treat brain lymphoma: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called acalabrutinib in 49 people with central nervous system lymphoma that has returned or not responded to prior therapy. The goal is to find the safest dose and see how well it shrinks tumors. Participants take the drug by mouth and are monitored for si…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New cocktail targets Hard-to-Treat brain lymphoma
Disease control OngoingThis study tests a combination of six drugs (TEDDI-R) for people whose aggressive B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this mix can control the cancer better than current treatments. About 48 adults will take the drugs in 21-day cycles for…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New combo aims to tame chemo side effects in brain cancer patients
Disease control OngoingThis study tests whether adding a drug called Voraxaze (glucarpidase) to the standard treatment of methotrexate and rituximab can safely lower methotrexate levels in the blood of people with central nervous system lymphoma. About 58 participants will receive the combination, and …
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC